However, in our experimental conditions, CCL2 expression decreased in PBMCs, D3 and AT lysates in the BBB models with PBMCs from moderate AD patients, versus that in the BBB models with PBMCs from mild AD patients by 1.97-fold, 1.71-fold, and 1.76-fold respectively (Fig 1). The gene discussed is CCL2; the disease is Alzheimer disease.